Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06462014 · ClinicalTrials.gov registry record
Description of Relugolix Use in Patients With Prostate Cancer Within the VHA
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 507
- Enrollment target
NCT06462014: Completed study, sponsored by Pfizer.
NCT06462014 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 507 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06462014 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 507 participants
- Enrollment target
Study Summary
The purpose of this real-world study is the learn about the demographics and clinical characteristics of patients with prostate cancer who initiated relugolix
Primary Outcome
The number of participants according to geographic regions of the United States (South, West, Northeast and Midwest) as documented during baseline period were reported in this outcome measure. Baseline period was 1 year prior to index date; index date was the initiation date of relugolix (anytime between 18-Dec-2020 to 31-Dec-2023) on or after the first observed prostate cancer diagnosis.
Interventions
- DRUG Relugolix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 507 participants |
| Start Date | 2024-06-19 |
| Est. Completion | 2024-12-13 |
What the finished NCT06462014 record still lists
NCT06462014 is an observational study that tracks outcomes without assigning an intervention. The registered 507 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Relugolix is the first listed.
NCT06462014 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06462014 about?
NCT06462014 is a clinical study titled "Description of Relugolix Use in Patients With Prostate Cancer Within the VHA". The purpose of this real-world study is the learn about the demographics and clinical characteristics of patients with prostate cancer who initiated relugolix
What is the current status of trial NCT06462014?
This trial is currently completed. The enrollment target is 507 participants. The study started on 2024-06-19. Estimated completion is 2024-12-13.
What interventions are being tested in trial NCT06462014?
The interventions under investigation include: Relugolix (DRUG).
Who is sponsoring clinical trial NCT06462014?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06164717 · 507 participants · NA
Behavioral and Neural Characteristics of Adaptive Speech Motor Control
- NCT02115295 · 508 participants · Phase 2
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
- NCT04692675 · 508 participants · NA
Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer
- NCT07391657 · 508 participants · Phase 3
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI